Delivering unique monoclonal antibodies against membrane receptors and haptens
SYnAbs' mission is to generate innovative antibodies against
poor immunogenic compounds &
Either as a custom service,
or as a catalog product,
you can benefit
from SYnAbs technologies
to get access to
singular monoclonal antibodies.
Raising antibodies against difficult to express antigens
Generating antibodies against conformation sensitive targets thanks to proprietary DNA and whole cell immunization technologies
>99% success rate for small, difficult and poor immunogenic antigens
Extreme specificity monoclonal antibodies
Higher affinity monoclonal antibodies
Access to multiple immune repertoires
Additional epitope recognition
Time to enjoy your free ebook :
"Proven strategies for successful antibodies generation against difficult antigens"
Where to meet SYnAbs in 2022?
March 28th - March 30th
March 29th - April 1st
April 15th - April 16th
Sept 20th - Sept 24th
Sept 28th
Oct 13th - Oct 15th
Oct 25th - Oct 27th
Nov 15th - Nov 18th
Dec 7th - Dec 9th
BioEurope Spring
Festival of Biologics
Innovation for Health
Life Science Baltics
Knowledge for Growth
BioJapan
BioEurope Fall
Medica
BioFIT
Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.
MENAC - Modifications Epigénétiques des Nucléosomes Associés au Cancer
Le projet MENAC a pour objectif de développer de tests innovants non invasifs pour la détection précoce
de différents types de cancers.
Ce projet réalisé en partenariat par les sociétés Volition et Synabs passe par la création d'anticorps monoclonaux
et la mise au point de nouveaux immuno-essais diagnostiques et théranostiques.
Subvention de 1.990.798€
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
+32 (0)71/374.880
BE 0637.716.206
